3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
61
Carcinoma, Renal Cell
39
Neoplasm Metastasis
38
Neoplasms
24
Kidney Neoplasms
20
Neuroendocrine Tumors
19
Recurrence
16
Prostatic Neoplasms
15
Head and Neck Neoplasms
13
Tuberous Sclerosis
12
Triple Negative Breast Neoplasms
12
Lymphoma, Mantle-Cell
11
Hodgkin Disease
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma
10
Colorectal Neoplasms
10
Waldenstrom Macroglobulinemia
9
Stomach Neoplasms
9
Multiple Myeloma
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Glioma
9
Glioblastoma
9
Brain Neoplasms
9
Sarcoma
8
Pancreatic Neoplasms
8
Melanoma
8
Lymphoma, Follicular
8
Lung Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Interventions
Fulvestrant
5
dalpiciclib
3
Letrozole
3
ribociclib
2
palbociclib
2
fluzoparib
2
exemestane
2
apatinib
2
Anastrozole
2
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pyrotinib
1
pegfilgrastim
1
patritumab deruxtecan
1
olaparib
1
irinotecan sucrosofate
1
abemaciclib
1
Zoledronic Acid
1
Rogaratinib
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Neoadjuvant Therapy
1
Liposomes
1
Irinotecan
1
Ga(III)-DOTATOC
1
Everolimus
1
Cell Separation
1
Capecitabine
1
Bevacizumab
1
Aromatase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Breast Cancer Metastatic
×
Everolimus
×
Clear all
NCT02511639
2020-12-03
MAIN-A
Istituto Oncologico Veneto IRCCS
Phase 3
Completed
110 enrolled